G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
Abstract Pathogenic mutations in LRRK2 cause Parkinson’s disease (PD). The G2019S variant is the most common, which results in abnormally high kinase activity. Compounds that target LRRK2 kinase activity are currently being developed and tested in clinical trials. We recently found that G2019S LRRK2...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-03-01
|
Series: | npj Parkinson's Disease |
Online Access: | https://doi.org/10.1038/s41531-024-00660-y |